
About CytomX
CytomX is a publicly listed company based in Santa Barbara (United States) founded in 2008. Probody therapeutics are developed for cancer treatment. It operates on a HealthTech model. CytomX has raised $135.62 million across 9 funding rounds from investors including Fidelity Investments, HHS and Canaan. The company has 121 employees. CytomX has completed 1 acquisition, including clinomicslabs.net. Its website cytomx.com draws about 18 thousand monthly visits. CytomX offers products and services including Probody Therapeutics. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is CytomX Therapeutics, Inc. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.
Company details
CytomX Therapeutics, Inc. is engaged in the research and development of novel cancer treatments through its proprietary Probody platform. The company operates in the biopharmaceutical sector, aiming to create therapies that target cancer more effectively while reducing toxicity. Solutions are advanced through clinical-stage programs, with a focus on transforming patient outcomes in oncology.
- Headquarters Santa Barbara, United States
- Employees 121
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phoneβ’β’β’β’ β’β’β’β’
- Website cytomx.com
- Social LinkedIn X
- Legal Name Cytomx Therapeutics, Inc.
- Annual Revenue$76.2 M (USD)-44.82as on Dec 31, 2025
- Net Profit-$17.37 M (USD)-154.5as on Dec 31, 2025
- EBITDA-$18.19 M (USD)-167.96as on Dec 31, 2025
- Total Equity Funding$135.62M (USD)
in 9 rounds
- Latest Funding Round$70M (USD), Series D
Jun 2015
- InvestorsFidelity Investments
& 11 more
- Employee Count121
- Investments & Acquisitions
Products & Services of CytomX
CytomX offers a comprehensive portfolio of products and services, including Probody Therapeutics.
Innovative cancer therapies are developed using Probody technology.
Funding Insights of CytomX
CytomX has successfully raised a total of $135.62M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $70 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $135.62M
- Total Rounds 9
- Last Round Series D β $70M
- First Round $208,046
(Jun 2008)
- Investors Count 12
All 9 funding rounds of CytomX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $70M | Series D | β | Fidelity Investments | |
| Jan 2015 | $20M | Series C | β | Pfizer Venture Investments | |
| Aug 2012 | $12.6M | Series B | β | Canaan | β |
| Nov 2010 | $524,994 | Series B | β | β | β |
| Sep 2010 | $30M | Series B | β | Third Rock Ventures | |
| Mar 2010 | $2.5M | Seed | β | β | β |
| Jun 2009 | $260,910 | Grant | β | β | |
| May 2009 | $260,910 | Grant | β | β | |
| Jun 2008 | $208,046 | Grant | β | β |
12 investors in total: 12 institutional.
Investors in CytomX
CytomX has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, HHS and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Corporate-backed venture capital firm focused on the healthcare sector | roche.com/venturefund.htm | |||
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Investment advisory services are provided to financial clients. | 1986 | teklacap.com | Boston, United States |
Investor details for CytomX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CytomX
57 people are tracked at CytomX (28 in leadership, 13 in board & advisors, 16 in team); the tracked headcount is 121.
| Name | Role | Group |
|---|---|---|
Madan Paidhungat | Vice President | Leadership |
Lloyd A. Rowland | SVP, General Counsel, Secretary & Chief Compliance Officer | Leadership |
Michael Kavanaugh | Chief Scientific Officer & Head of Research and Non-Clinical Development | Leadership |
Farooq Nomani | Sr. Director, Corporate Counsel | Leadership |
Dylan Daniel | Vice President, Oncology & Immuno-oncology Research And Translational Biology | Leadership |
Irene Franklin | Senior Director, Drug Safety & Pharmacovigilance (consultant) | Leadership |
Rachael Lester | Chief Business Officer | Leadership |
Chris Ogden | CFO | Leadership |
Lindsay Yamamoto | Executive Director, Human Resources | Leadership |
Wayne Chu | Senior Vice President, Chief Medical Officer | Leadership |
Christine Sterling | Executive Assistant To Chief Executive Officer | Leadership |
Yihsuan Shannon Tsai | Senior Director, Head Of Bioinformatics & Computational Biology | Leadership |
Olga Vasiljeva | Vice President, Platform Biology, Bioanalysis And Clinical Pharmacology | Leadership |
Kakali Dhar | Director of Bioanalysis, Platform Biology and Bioanalysis | Leadership |
Mei Wang, CPA, MBA | Director, SEC Reporting and Technical Accounting | Leadership |
Michael Winter | Director, Platform Biology And Bioanalysis | Leadership |
Francesco Caiazza | Associate Director, Translational Biology | Leadership |
Sharad Kukreti | Head of FP&A and Procurement | Leadership |
Stephanie Robertson | Senior Vice President, Alliances & Program Leadership | Leadership |
Rohit Shete, CCRA | Associate Director, Clinical Operations | Leadership |
37 more people are available in the full profile.
Complete people profiles for CytomX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CytomX
CytomX is a publicly listed company on the NASDAQ with ticker symbol CTMX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Oct 2015
- Listed onNASDAQ: CTMX
- Listed entityCytomX Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS23284F1057
- Share price$2.33 (-3.93% on the day) · 2026-10-13
- Market capitalisation$506.6M
- Price to earnings10.3
- EPS (diluted, trailing year)$-0.46
- Volume (last session)5,223,013
Financials of CytomX
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $76.2M | -$17.4M | -$18.2M |
| 2024 | $138.1M | $31.9M | $26.8M |
| 2023 | $101.2M | -$569,000 | -$4.3M |
| 2022 | $53.2M | -$99.3M | -$87.8M |
| 2021 | $37.3M | -$115.9M | -$110.2M |
Detailed financial statements for CytomX
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CytomX
CytomX has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include clinomicslabs.net.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Medical research laboratory services are provided by Clinomics Labs. | clinomicslabs.net | 0 | Jun 2004 | $3.98M |
Complete acquisition details for CytomX
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of CytomX
5 dated milestones of CytomX across 11 years, from founding to its latest funding, stage changes and deals.
- Acquisition Acquires clinomicslabs.net.
- Founded CytomX is founded.
- Funding First funding round of $208K.
- Funding Latest funding round, Series D, of $70.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of CytomX
CytomX has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of CytomX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CytomX
The website of CytomX (cytomx.com) receives about 17.7K visits a month and ranks #2,633,987 among all websites worldwide, #3,598 in Biotechnology and Pharmaceuticals.
- Monthly visits17.7K
▲ 120.6% vs previous month
- Unique visitors3.6K
per month
- Global rank#2,633,987
among all websites
- Category rank#3,598
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.8
- Average visit36 sec
- DevicesDesktop 43% Β· Mobile 57%
Websites whose visitors overlap most with CytomX. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| visterrainc.com | 100% | 2.5K | #6,988,741 | View details | |
| insmed.com | 100% | 68.8K | #433,178 | View details | |
| immunocore.com | 100% | 11.9K | #2,192,904 | View details | |
| intarcia.com | 99% | View details | |||
oncobiologics.com | oncobiologics.com | 98% | #5,583,393 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 6 similar websites and full traffic analytics for CytomX
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as CytomX (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cytomx
Complete news archive for CytomX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CytomX
CytomX was founded in 2008.
CytomX is headquartered in Santa Barbara, United States. It is registered at Santa Barbara, California, United States.
CytomX is a funded company, having raised a total of $135.62M across 9 funding rounds to date. The company's 1st funding round was a Grant of $208.05K, raised on Jun 2008.
CytomX has 121 employees.
Annual revenue of CytomX is $76.2M as on Dec 31, 2025.
CytomX Therapeutics, Inc. is engaged in the research and development of novel cancer treatments through its proprietary Probody platform. The company operates in the biopharmaceutical sector, aiming to create therapies that target cancer more effectively while reducing toxicity. Solutions are advanced through clinical-stage programs, with a focus on transforming patient outcomes in oncology.
CytomX's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.
CytomX offers Probody Therapeutics.
Yes, CytomX is publicly traded on NASDAQ under the ticker symbol CTMX.
CytomX has made 1 acquisition, including clinomicslabs.net.
CytomX has 12 investors. Key investors include Fidelity Investments, HHS, Canaan, Perceptive Advisors, and Tekla Capital Management.
CytomX operates through Cytomx Therapeutics, Inc..
